RESEARCH MONOGRAPH · KDC-MN-316
Pramipexole
Pramipexole, sold as Mirapex, is a non-ergot dopamine agonist that prefers D3 receptors over D2 by about eightfold. That subtype preference may matter because D3 receptors cluster in mood-related brain regions, which has driven research interest in pramipexole for treatment-resistant depression in addition to its FDA-approved uses in Parkinson disease and restless legs syndrome. The compound is one of the cleanest dopamine agonists in terms of off-target binding, but it carries a well-documented risk of impulse control disorders (gambling, compulsive shopping, hypersexuality) that emerge in a meaningful minority of patients. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Non-ergot D2/D3-preferring dopamine agonist
A non-ergot benzothiazole D3-preferring dopamine receptor agonist; first-line for Parkinson disease and restless legs syndrome.
Abstract
Pramipexole ((6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; CAS 104632-26-0; molecular formula C10H17N3S; molecular weight 211.32) is a non-ergot benzothiazole dopamine receptor agonist developed at Boehringer Ingelheim and approved by the FDA in 1997 under the trade name Mirapex. The compound is D3-preferring (D3 Ki approximately 0.5 nM, D2 Ki approximately 4 nM, ratio approximately 8) with minimal activity at non-dopaminergic receptors, distinguishing it from ergoline agonists by absence of the rare cardiac valvulopathy and serosal fibrosis associated with the ergot agonists. Plasma half-life is 8 to 12 hours; metabolism is minimal (90 percent renal excretion unchanged). Approved for Parkinson disease, restless legs syndrome. Off-label use in treatment-resistant unipolar and bipolar depression at higher doses (up to 4.5 mg) is supported by mechanistic rationale (D3 receptor predominance in mesolimbic reward circuits) and small clinical trials. The dopaminergic activity produces a recognized risk of impulse control disorders (pathological gambling, hypersexuality) in approximately 14 percent of long-term users.
Mechanism of action
Non-ergot D3-preferring dopamine receptor agonist (~8-fold over D2). Minimal off-target activity. Risk of impulse control disorders.
Reported research dose ranges
Clinical 0.125 to 4.5 mg in the published literature or ER. Rodent studies 0.1 to 3 mg/kg.
References
- Mierau J, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995.
- Rektorova I, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease. Eur J Neurol 2003.
- Voon V, et al. Impulse control disorders and dopaminergic medications in Parkinson's disease. Curr Opin Neurol 2006.
Read the full monograph
The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.